In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.
This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.
What is Givinostat?
Givinostat is a histone deacetylase (HDAC) inhibitor, a class of drugs that block enzymes involved in gene regulation. By inhibiting HDAC activity, givinostat aims to activate muscle repair mechanisms, reduce inflammation, and decrease fibrosis in muscle tissues, thereby slowing the progression of DMD.
Approval Details
The MHRA’s conditional approval allows givinostat to be used in patients with DMD who are six years of age and older, and it is applicable to all genetic variants of the condition.
This decision follows the U.S. Food and Drug Administration’s (FDA) approval of givinostat earlier this year.
Clinical Trial Outcomes
The approval is based on data from a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. The study involved 179 boys with DMD, aged 6 years and older, who were treated with either givinostat or a placebo for 72 weeks.
The results showed that givinostat significantly slowed the decline in muscle function compared to the placebo group, as measured by the four-stair climb assessment.
The Drugs Benefits and Side Effects
- Slower Disease Progression: Givinostat demonstrated a smaller decline in muscle function over the study period compared to the placebo group.
- Common Side Effects: The most common adverse events reported were diarrhoea and vomiting, but no treatment-related deaths occurred.
Early Access Programme
Future Prospects and Next Steps
The approval of givinostat not only diversifies treatment pathways for DMD but also opens up possibilities for combination therapies.
Ongoing developments in gene therapy, exon skipping drugs, and muscle regeneration therapies further enhance the future prospects for addressing the unmet needs in DMD treatment. Despite awaiting full UK licensure, authorities have made significant progress by conditionally approving givinostat.
The National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) will need to recommend its use for it to be widely available in England, Wales, Northern Ireland, and Scotland.
The Takeaway
A New Era in DMD Treatment
The conditional approval of givinostat by the MHRA marks a promising new era in the treatment of Duchenne muscular dystrophy. With its potential to slow disease progression and its availability through early access programmes, givinostat offers renewed hope for patients and their families.
Sources: THX News & Medicines and Healthcare products Regulatory Agency.
